Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
The transaction is expected to close in the first quarter of 2022
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
Biogen paid Ionis a US $ 60 million one-time upfront payment
It has also been granted permission to conduct trials for booster dose
Subscribe To Our Newsletter & Stay Updated
